Vineet Laboratories
- Market cap
- ₹ 71 Cr.
- P/E
- 19.8x
- P/B
- 1.57x
- 52-week range
- 27.96 – 43.5
- ROE
- 4%
- ROCE
- 8.5%
- Dividend yield
- 0%
- Debt / equity
- 0.99
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Vineet Laboratories Limited is an India-based company engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates products include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. The Company also exports API intermediates, fine chemicals, and custom synthesis molecules.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Vineet Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.8 against a typical 34.3: cheaper than most peers (1st = cheapest).58th of 220
- Sales growth+34.2% against a typical +15.6% from a year earlier.48th of 197
- Share price, 3 months−5.7% against a typical −0.5%.127th of 200
- Size₹ 70.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).159th of 199
Latest announcements
Exchange filings and their impact on the company.
- Q1 FY27 beats full FY26 profit on 40% sales growth and 22% margins, pointing to sharply higher full-year earnings.
Vineet Laboratories reported unaudited results for the quarter ended June 30, 2026 with net sales of Rs 10.39 crore versus Rs 7.44 crore a year ago and net profit of Rs 1.51 crore versus a loss of Rs 0.87 crore. Profit before tax was Rs 0.79 crore, boosted by a Rs 0.73 crore deferred tax credit, and EPS was about Rs 0.79. The strong Q1, seasonally the weakest quarter last year, already exceeds the full FY26 profit of Rs 1.11 crore, indicating a sharp turnaround in scale and profitability.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 26 Oct 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 30 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 14 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 along with the limited review report. |
| 27 Nov 2025 | Fund Raising | To consider and approve the proposal of Fund Raising by way of issue of equity shares through Rights Issue. |
| 8 Nov 2025 | Financial Results | To consider and approve the financial results for second quarter & the half year ended on September 30, 2025 along with the limited review report |
| 23 Oct 2025 | Financial Results | To consider and approve the unaudited standalone financial results of the Company for the Second quarter and Half Year ended on September 30, 2025 along with the Limited Review Report. |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 43 | 33 | 37 | 24 | 19 | 18 | 14 | 7 | 17 | 16 | 19 |
| Expenses | 37 | 39 | 33 | 34 | 25 | 19 | 22 | 25 | 7 | 14 | 13 | 16 |
| Operating Profit | 0 | 4 | −1 | 3 | −1 | −0 | −4 | −11 | 0 | 3 | 2 | 2 |
| OPM % | 0.7% | 9.6% | −2% | 9.2% | −3.3% | −1.6% | −22.8% | −78.4% | 4.2% | 18.3% | 15.9% | 13.2% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −1 | 3 | −2 | 1 | −2 | −2 | −6 | −11 | −1 | 0 | 1 | 1 |
| Tax % | −2.3% | 4.7% | −11.1% | −34% | −1.8% | 7% | 0.5% | −6.2% | −4.4% | −8.1% | −3.7% | 27.3% |
| Net Profit | −1 | 2 | −2 | 2 | −2 | −2 | −6 | −11 | −1 | 0 | 1 | 1 |
| EPS in Rs | −0.65 | 1.26 | −1.08 | 1 | −1.11 | −0.95 | −2.97 | −5.48 | −0.45 | 0.21 | 0.44 | 0.38 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- −25%
- 3 Years
- −35%
- TTM
- −21%
- 10 Years
- —
- 5 Years
- −9%
- 3 Years
- −4%
- TTM
- 105%
- 10 Years
- —
- 5 Years
- −11%
- 3 Years
- −5%
- TTM
- —
- 10 Years
- —
- 5 Years
- −8%
- 3 Years
- −23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vineet Laboratories | ₹ 36.99 | ₹ 71 Cr. | 19.8x | 1.6x | 4% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Satyanarayana Raju Bhupathiraju
- Chief Financial Officer, Whole Time Director
- Gaddam Venkata Ramana
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.